Patent Application
20200069366
The present disclosure relates to methods, devices, kits and systems for enhancing the efficacy and longevity of denervation procedures.
Existing technology used for denervation primarily includes radiofrequency ablation, which is commonly performed in a monopolar configuration where current is passed between a probe and a ground pad. Unfortunately, nerve fibers may regenerate over time, leading to the need for repeated denervation procedures. The present disclosure pertains to devices and methods for use in inhibiting nerve regeneration after the performance of denervation procedures, including radiofrequency ablation denervation procedures.
In one aspect, a system is described herein for denervation including a catheter including a radially expandable member, the radially expandable member including an exterior surface, a plurality of electrodes on the exterior surface configured for delivery of energy during a denervation procedure in a vessel, and a chemical agent coating on the exterior surface, wherein the chemical agent inhibits or prevents nerve regeneration. The radially expandable member is configured to have a first unexpanded configuration and a second expanded configuration, and is configured to bring the exterior surface in contact with a wall of a vessel when it is in the expanded configuration.
In one aspect, the system is configured for electrical current flow between the plurality of electrodes. In one aspect, the radially expandable member is a selected from a group consisting of a balloon, an elongate balloon, a shape-memory spiral, a stent, a spline structure, a basket structure, and a wireframe structure.
In one aspect, the radially expandable member is an elongate balloon and the system is configured to generate an elongate denervation treatment pattern. In one aspect, the catheter comprises an inflation lumen in fluid communication with the radially expandable member. In one aspect, the radially expandable member defines openings, the system includes a fluid for filling the inflation lumen, inflating the radially expandable member, and for dispensing through the openings in the radially expandable member.
In one aspect, the radially expandable member is a shape-memory spiral, having a first, elongate, linear configuration and a second, radially-expanded, spiral configuration.
In one aspect, the chemical agent is selected from the group consisting of inhibitors of extracellular proteins, inhibitors of neurotropic factors, inhibitors of neuropoetins, inhibitors of neurotropic factor receptors, inhibitors of cell adhesion molecules, inhibitors of cell signaling molecules, inhibitors of cell, inhibitors of cytokines and chemokines, inhibitors of sulfate proteoglycans, inhibitors of enzymes, inhibitors of arginase, inhibitors of 13-secretase, inhibitors of urokinase-type and tissue-type plasminogen activators, inhibitors of myelin-derived molecules, semaphorin-3A, paclitaxel, fibrin, brain-derived neurotrophic factor (BDNF), myelin-derived factors, phosphatase and tensin homolog (PTEN), suppressor of cytokine signaling 3 (SOCS3) gene, notch/lin12 proteins, and ZnEgr proteins.
In one aspect, the system is configured to measure impedance between combinations of the electrodes. In one aspect, the system is configured to measure impedance a reference pad on the patient's skin and one or more electrodes.
In one aspect, the radially expandable member is configured to contact a wall of a hepatic vessel when the radially expandable member is in the expanded configuration.
In one aspect, the radially expandable member comprises a wireframe structure having a plurality of wires extending from a proximal end to a distal end, wherein each wire including one of the electrodes, wherein each electrode defines part of the exterior surface including the chemical agent coating.
In one aspect, the radially expandable member comprises a shape-memory ribbon spiral and having an exterior side and interior side, wherein the exterior side defines the exterior surface, wherein the electrodes and the chemical agent coating are present on one side of the ribbon spiral.
In one aspect, a system is described herein for denervation including a catheter including an inflation lumen and an elongate balloon in fluid communication with the inflation lumen, the elongate balloon including an exterior surface, a plurality of electrodes on the exterior surface configured for delivery of energy during a denervation procedure in a vessel, and a chemical agent coating on the exterior surface, wherein the chemical agent inhibits or prevents nerve regeneration. The elongate balloon is configured to have a first unexpanded configuration and a second expanded configuration, wherein the elongate balloon is configured to bring the exterior surface in contact with a wall of a vessel when it is in the expanded configuration.
In one aspect, the radially expandable member is configured to contact a wall of a hepatic vessel when the radially expandable member is in the expanded configuration.
In one aspect, a method of treatment is described herein including providing a catheter including a radially expandable member and a plurality of electrodes on an exterior surface of the radially expandable member configured for delivery of energy during a denervation procedure in a vessel. The catheter further includes a chemical agent coating on the exterior surface. The method includes expanding the radially expandable member from a first unexpanded configuration to a second expanded configuration, wherein the radially expandable member is configured to bring the exterior surface in contact with a wall of a vessel when it is in the expanded configuration. The method includes conducting a denervation procedure using electrical energy at a target site in a subject using the electrodes of the radially expandable member. The method includes introducing at least one chemical agent that inhibits or prevents nerve regeneration to the target site, wherein the chemical agent is present in the chemical agent coating on the exterior surface of the radially expandable member.
In one aspect, the denervation procedure is an irreversible electroporation procedure. In one aspect, the denervation procedure is a radiofrequency ablation (RFA) procedure.
In one aspect, conducting the denervation procedure and introducing the at least one chemical agent occur simultaneously. In one aspect, the method includes measuring impedance between combinations of the electrodes.
In one aspect, the radially expandable member contacts a wall of a hepatic vessel when the radially expandable member is in the expanded configuration.
This summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which is not to be taken in a limiting sense. The scope herein is defined by the appended claims and their legal equivalents.
While embodiments are susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the scope herein is not limited to the particular aspects described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope herein.
The present disclosure provides an improved hepatic denervation therapy for metabolic disorders, in which hepatic denervation is performed using a first therapy such as radiofrequency ablation, irreversible electroporation, or other modality, and then the nerves are prevented from regenerating using a second therapy such as drug delivery of nerve growth inhibitors. Specific nerve growth inhibitors are disclosed. In some examples, the system is self-contained in a single device. In alternative examples, the system can include multiple separate devices.
The disclosed technology provides a medical treatment for medical conditions including any condition requiring the regulation of blood glucose levels, most notably diabetes, but also including insulin resistance, genetic metabolic disease, hyperglycemia, obesity, hyperlipidemia, hypertension, endocrine diseases and/or inflammatory disorders. The medical device and system including a first medical device capable of reducing sympathetic activity to control hepatic glucose production. The system also provides a nerve growth inhibitor or blocking agent. The medical device can be a catheter capable of delivering a nerve growth inhibitor or blocking agent to the treated nerve tissue to reduce the rate of nerve regeneration.
The disclosed technology provides a method that includes delivering a first treatment which at least temporarily reduces nerve signals to the liver to decrease hepatic glucose production. The method further includes delivering a second treatment which impairs the nerves' ability to regenerate and/or prevents the nerves from regaining full function. The first treatment can include hepatic denervation of nerve tissue using electrical energy, radiofrequency energy, irreversible electroporation, microwave energy, ultrasound energy, focused ultrasound (e.g. high-intensity focused ultrasound (HIFU), low-intensity focused ultrasound (LIFU)), laser energy, infrared energy, light energy, thermal energy, steam or heated water, magnetic fields, reversible electroporation, cryogenic therapy, brachytherapy, ionizing therapy, drug delivery, biologic delivery, chemical ablation (e.g. ethanol), mechanical disruption, any other therapy modality to cause disruption or modulation of the target tissue, or any combination thereof. The second treatment can include delivering a nerve growth inhibitor to the treated tissue.
In some examples, electroporation therapy is delivered concurrently with or in a time period close to the nerve growth inhibitor treatment to increase penetration of the nerve growth inhibitor into the hepatic vessel wall. In some examples, the nerve growth inhibitor and optional electroporation are delivered before, during, or after denervation therapy, such as radiofrequency ablation, irreversible electroporation, and others. In some examples, the nerve growth inhibitor and optional electroporation are delivered first via a first catheter, and then a second catheter delivers denervation therapy. In some examples, the denervation therapy is delivered first via a first catheter, and then a second catheter delivers nerve growth inhibitor and optional electroporation.
In addition or alternatively, in some example, the time period within which both denervation therapy and nerve growth inhibitor treatment are delivered is within the time period of one minimally-invasive procedure, such as within five hours, within four hours, within three hours, within two hours, within one hour, within 45 minutes, within 30 minutes or within 15 minutes.
Referring now to
In various examples, the radially expandable member 110 is an inflatable elongate balloon which moves from the unexpanded configuration to the expanded configuration by being inflated. As used herein, elongate means a structure is longer than wide. To inflate the balloon, the catheter assembly 108 includes an inflation lumen and an inflation port 118 that are in fluid communication with the balloon interior. In various examples, an inflation fluid provided to inflate the balloon can be sterile water or saline solution. In addition or alternatively, the inflation fluid may include a chemical agent that inhibits nerve growth, and that inflation fluid may be dispersed to the vessel wall, such as by weeping from openings in the balloon, to deliver the chemical agent to the lumen of the vessel.
The radially expandable member 110 also includes a chemical agent coating 116 on the exterior surface, wherein the chemical agent inhibits or prevents nerve regeneration. In some examples, the chemical agent is a nerve growth inhibitor selected from the group consisting of semaphorin-3A, paclitaxel, fibrin, brain-derived neurotrophic factor (BDNF), myelin-derived factors, phosphatase and tensin homolog (PTEN), suppressor of cytokine signaling 3 (SOCS3) gene, notch/lin12 proteins, and ZnEgr proteins. Other examples of chemical agents can be used with the systems described herein, and some of these additional examples are described herein.
The catheter assembly 108 includes a catheter body 119 having a distal end 120 and a proximal end 122. The inflation lumen is a passage within the catheter body 108. The distal end 120 defines a distal guidewire port 124. The proximal end 122 of the catheter body 108 is attached to a housing 128 that includes the inflation port 118, the proximal guidewire port 130, and an electrical connector 134. The catheter body 108 may define a sheath, such that the radially expandable member 110 can be contained within the sheath when the radially expandable member is in the unexpanded state.
The electrical connector 134 connects the catheter assembly 108 to the generator and control device 104, which includes a plurality of electrical connections and is configured to deliver controlled energy to the electrodes 112. The generator and control device 104 includes a display 138, user input devices 140, an energy source 142, a controller 144, and a sensing circuit 146.
The energy source 142 may provide electrical energy, radiofrequency energy, irreversible electroporation, microwave energy, ultrasound energy, focused ultrasound (e.g. high-intensity focused ultrasound (HIFU), low-intensity focused ultrasound (LIFU)), laser energy, infrared energy, light energy, thermal energy, steam or heated water, magnetic fields, reversible electroporation, cryogenic therapy, brachytherapy, ionizing therapy, drug delivery, biologic delivery, chemical ablation (e.g. ethanol), mechanical disruption, any other therapy modality to cause disruption or modulation of the target tissue, or any combination thereof. The sensing circuit 146 can be configured to determine the impedance between combinations of electrodes. Impedance information indicates if the electrodes are in contact with a vessel wall, and indicates progress of the treatment. The display 138 may include a graphical user interface indicating which electrodes are in contact with a vessel wall, watts of energy, degrees Celsius at a temperature sensor, number of seconds of treatment time left, and which electrodes are active. User input devices 140 include buttons, switches, touch screen, a keyboard, or other devices to provide input and instructions to the generator and control device 104.
Examples of generator and control devices, energy delivery structures, electrode configurations, and energy delivery methods useable with the embodiments disclosed herein are disclosed in U.S. Pat. App. Pub. No. US 2012/0095461, entitled “Power Generating and Control Apparatus for the Treatment of Tissue”, issued as U.S. Pat. No. 9,277,955 and assigned to Vessix Vascular, Inc., which are incorporated by reference herein. Further examples are disclosed in U.S. Pat. No. 9,037,259, entitled “Methods and apparatuses for remodeling tissue of or adjacent to a body passage”, assigned to Vessix Vascular, Inc., and incorporated by reference herein. Further examples useable with the embodiments disclosed herein are disclosed in U.S. Pat. No. 7,742,795 entitled “Tuned RF Energy for Selective Treatment of Atheroma and Other Target Tissues and/or Structures”, U.S. Pat. No. 7,291,146 entitled “Selectable Eccentric Remodeling and/or Ablation of Atherosclerotic Material”, and U.S. Pub. No. 2008/0188912 entitled “System for Inducing Desirable Temperature Effects on Body Tissue”, which are assigned to Vessix Vascular, Inc., the full disclosures of which are incorporated herein by reference. Combinations of the structures and methods described in the present application and the incorporated documents may be used.
Now referring to
In some examples, the electrodes 112 are arranged on the elongate balloon to form an elongate denervation treatment pattern. In some examples, the system is configured to measure impedance between combinations of the electrodes 112. As shown in
The exterior surface 114 is provided with a chemical agent coating 116 including a chemical agent that prevents or reduces nerve regeneration. The use of such a chemical agent can reduce the need to repeat a denervation procedure and extend the timeframe of the beneficial effects of the denervation procedure. In various examples, the chemical agent coating is present where the radially expandable member 110 is expected to contact a vessel wall when it is in an expanded configuration, such as the portion of the radially expandable member that is cylindrical and has the maximum diameter in the expanded configuration. In various examples, the chemical agent coating is present on portions of the exterior surface of the radially expandable member 110. In various examples, the chemical agent coating is not present on the electrodes 112. In various examples, the chemical agent coating is present on the portions of the radially expandable member 110 that are not occupied by the electrodes 112.
In some examples, the radially expandable member is a shape-memory member, having a first, elongate, linear configuration and a second, radially-expanded configuration. The shape-memory member can include or be made from shape retention material or a shape-memory material such as a shape-memory alloy. Examples of shape-memory material are nickel titanium alloy, also known as nitinol, copper aluminum nickel alloy, and stainless steel. A shape-memory material as used herein is a material that “remembers” its original shape and that when deformed returns to its pre-deformed shape. A shape retention material is a material that retains its shape once positioned.
In various examples, the radially expandable member is a shape-memory spiral, having a first, elongate, unexpanded configuration and a second, radially-expanded, spiral configuration.
In
In various examples, the radially expandable shape-memory spiral member has a circular cross-section or an oblong cross-section, such as a rectangular or ribbon cross-section.
In various examples, the diameter of the shape-memory spiral in its expanded state is sized to ensure intimal contact with the inner diameter of the lumen. Examples of diameters and other dimensions for radially expandable members such as a shape-memory spiral are provided herein.
Where the shape-memory spiral has an oblong shape such as a ribbon shape, the ribbon width, or catheter cross-sectional diameter in various examples is at least about 0.05 mm, at least about 0.3 mm, at least about 0.5 mm, at most about 5 mm, at most about 3 mm, at most about 2 mm, at least about 0.05 mm and at most about 5 mm, at least about 0.3 mm and at most about 3 mm, or at least about 0.5 mm and at most about 2 mm. A shape-memory spiral with a round cross-sectional shape can also have these cross-sectional diameters in various embodiments.
In various examples, the chemical agent coating is not present on the shape memory spiral. A chemical agent can be applied to the treatment area using a separate device, such as a balloon device with a coated surface or a balloon device filled with a chemical agent, to name a few examples, before or after denervation therapy.
The wireframe structure 610 includes a plurality of wires 616 extending from a proximal end 618 of the structure to a distal end 620 of the structure. Each wire supports at least one of the electrodes. In various examples, each wire 616 supports two electrodes, three electrodes, four electrodes, five electrodes, six electrodes, or another number of electrodes. Each electrode 612 defines part of an exterior surface of the radially expandable member. Portions of the exterior surface of the radially expandable member include the chemical agent coating.
A catheter body 608 may define a sheath, such that the radially expandable member 610 can be contained within the catheter body 608 when the radially expandable member is in the unexpanded state. The wires 616 may include a shape-memory material such as nitinol. The wireframe structure 610 is formed to have an expandable basket shape in various examples. In various examples, the wireframe structure 610 is attached to a rod at its proximal end 618 within catheter body 608. In various examples, the rod can be used to push the wireframe structure 610 out of catheter body 608, causing the wireframe structure 610 to spring into its expanded shape. When the rod is pulled in a proximal direction, the wireframe structure 610 is pulled in catheter body 608, is constrained, and takes on its unexpanded shape.
In addition or alternatively, a distal rod can extend to the distal end 620 of the wireframe structure 610. The push and pull of the distal rod can cause the basket to expand and collapse. For such a design, the wires 616 may not need to rely on a shape-memory material such as nitinol, and can instead be made of a shape retention material such as stainless steel. In addition or alternatively, the wires 616 can be made of a flexible circuit. One example of such a flexible circuit is included in the INTELLAMAP ORION™ mapping catheter available from Boston Scientific Corporation Inc., headquartered in Marlborough, Mass., USA.
In various examples, the diameter of the wireframe structure in its expanded state is sized to ensure intimal contact with the inner diameter of the lumen. Examples of diameters and other dimensions for radially expandable members such as a wireframe structure are provided herein.
The electrode strip 712 may include one electrode, such as for a monopolar device, or multiple electrodes. The electrode or electrodes may be configured to deliver denervation therapy to a full 360 degree circumference of the lumen or to ranges of the circumference less than that, such as to at least about 30 degrees, at least about 45 degrees, at least about 60 degrees, at least about 90 degrees, at least about 120 degrees, at least about 150 degrees, at least about 180 degrees, at most about 180 degrees, at most about 210 degrees, at most about 240 degrees, at most about 270 degrees, at least about 30 degrees and at most about 270 degrees, or at least about 45 degrees and at most about 180 degrees. A spiral configuration of the electrode strip is does not delivery therapy to the full 360 degree circumference in the same axial location, thus reducing the potential for an acute reaction causing full constriction of the vessel.
The pores 714 may a diameter ranging from a 0.1 microns to 5 millimeters. In one example, there are several hundred pores 714 defined in the inflatable balloon 710 with each pore having a diameter of about 0.5 micron. The pores may be oriented on one side of the electrode strip, on both sides of the electrode strip as shown in
A pair of micro-needles 814 flanks each electrode 812 in the example of
The inflatable balloon 810 is connected to a catheter body 808 at a proximal end 818 of the inflatable balloon. The catheter body 808 may include an inflation lumen to inflate the balloon 810 from the unexpanded to the expanded configuration. The catheter body 808 may also include a sheath for the balloon 810 to be withdrawn into when it is in the unexpanded state.
In one example, the microneedles deploy or more fully deploy when the balloon is pressurized. In other words, the needles protrude more fully from an exterior surface of the balloon when pressure is applied internally. To avoid tissue damage during deliver of the balloon catheter, for example, snagging tissue with the needles, the balloon would be in a collapsed state and inside a delivery sheath during delivery of the balloon to the treatment site. The needles may protrude from the balloon surface in the range of 0.1 mm to 1 mm. The needles may serve to measure electrical impedance in local regions, deliver denervation therapy, such as radiofrequency energy, or both.
The balloon may include one or more needles near each electrode. In various examples, the needles are spaced apart by at least about 1 mm and at most about 10 mm. In various examples, the balloon includes at least about 2 microneedles and at most about 2000 microneedles, or at least about preferably 20 microneedles and at most about 200 microneedles, around the circumference of the balloon.
The catheter body 908 may include an inflation lumen to inflate the balloons 910, 911 from an unexpanded configuration to an expanded configuration. The catheter body 908 may also include a sheath for the balloons 910, 911 to be withdrawn into when they are in the unexpanded state. After the first and second balloons are deployed, spaced away from each other, and inflated, a nerve growth inhibitor 916 can be injected into and circulated within the space 914 in between the balloons. Residual nerve growth inhibitor can be removed before deflating the balloons.
In various examples, the diameter of the balloons when expanded is at least about 2 mm, at least about 3 mm, at most about 10 mm, at most about 5 mm, at least about 2 mm and at most about 10 mm, or at least about 3 mm and at most about 5 mm. A distance between the balloons can range from at least about 10 mm to at least about 50 mm.
The catheter assembly 900 can be configured to delivery electrical energy, for example, electroporation, to the fluid between the two balloons, to increase permeability of the nerve growth inhibitor into the vessel wall. The balloon material may include polyethylene teraphthalate (PET), a thermoplastic elastomer, such as PEBAX™ thermoplastic elastomer available from Arkema, having a business location in King of Prussia, Pa., USA, nylon, non-compliant balloon materials, and semi-compliant balloon materials.
A method of treatment according to various examples described herein includes providing a catheter including a radially expandable member and a plurality of electrodes on an exterior surface of the radially expandable member. The electrodes are configured for delivery of energy during a denervation procedure in a vessel. The radially expandable member also includes a chemical agent coating on the exterior surface.
The system may include a guidewire, and the catheter may include a guidewire passage. The catheter can be introduced to a treatment site in a patient's body by advancing the guidewire to the treatment site, advancing the catheter assembly over the guidewire until the distal end of the catheter assembly is near the treatment site, and advancing the unexpanded radially expandable member out of the catheter sheath. Other techniques for positioning the radially expandable member at the treatment site can also be used.
The radially expandable member is expanded from a first unexpanded configuration to a second expanded configuration. Many different types of radially expandable members can be used in this step, such as the examples described herein and in the incorporated documents. The radially expandable member is configured to bring the exterior surface in contact with a wall of a vessel when it is in the expanded configuration. In one example, the radially expandable member is configured to bring the exterior surface in contact with a wall of a hepatic vessel of a patient when it is in the expanded configuration.
A denervation procedure is conducted using electrical energy at a target site in a subject using the electrodes of the radially expandable member. The denervation procedure can be a radiofrequency ablation procedure, an irreversible electroporation procedure, or another denervation procedure including the other examples described herein and in the incorporated documents.
In various examples, the treatment site is within a vessel, lumen or other vasculature of a patient. In various examples, the radially expandable member is advanced to the treatment site through the vasculature of the patient. In other words, the radially expandable member is intravascularly delivered.
At least one chemical agent that inhibits or prevents nerve regeneration is introduced to the target site close in time to the denervation procedure. In various examples, the chemical agent is present in a chemical agent coating on the exterior surface of the radially expandable member. In other examples, there is no chemical agent coating on the exterior surface, and the chemical agent is injected into the vessel wall or circulated in the vessel at the target site. In some examples, a single catheter assembly is configured to perform the denervation procedure and deliver the chemical agent. In other examples, one catheter assembly provides the denervation procedure and a different catheter assembly delivers the chemical agent.
In some examples, the chemical agent is delivered after the denervation therapy. In some examples, the chemical agent is delivered simultaneous with the denervation therapy. In some examples, the nerve growth inhibitor contacts the surface of the vessel wall before denervation therapy is delivered. For example, in the case of a drug-coated balloon having electrodes on its surface, the drug would contact the inner surface of the vessel as soon as the balloon is inflated, before the denervation therapy is applied
The method may also include measuring impedance between combinations of individual electrodes. The method may also include measuring impedance between one or more electrodes and a reference ground pad located on a patient's skin. For example, the system may measure impedance between a first electrode and a ground pad, between a second electrode and a ground pad, or both. Measurement of impedance can provide information about the progress of the denervation procedure, the contact of electrodes with the vessel wall, and other information.
In various examples, the diameter of a radially expandable member in its expanded state is at least about 1 mm, at least about 2 mm, at least about 3 mm, at most about 20 mm, at most about 10 mm, at most about 7 mm, at least about 1 mm and at most about 20 mm, at least about 2 mm and at most about 10 mm, or at least about 3 mm and at most about 7 mm.
In various examples, the length of a radially expandable member in its expanded state is at least about 10 mm, at least about 20 mm, at most about 30 mm, at most about 50 mm, at least about 10 mm and at most about 50 mm, at least about 20 mm and at most about 30 mm, or about 25 mm.
Where the radially expandable member is a balloon, the balloon material may include polyethylene teraphthalate (PET), a thermoplastic elastomer, such as PEBAX™ thermoplastic elastomer available from Arkema, having a business location in King of Prussia, Pa., USA, nylon, non-compliant balloon materials, and semi-compliant balloon materials.
The nerve growth inhibitor used with any of the example medical devices described herein can include one of the following or a combination of the following agents. In various examples, the nerve growth inhibitor can be provided as a coating, as a liquid, or can be encapsulated in microparticles or nanoparticles within a biodegradable shell. Encapsulated configurations can allow modulated release of the nerve growth inhibitor over the course of up to three months.
Classes of nerve growth inhibitors include inhibitors of extracellular proteins such as laminin, fibronectin, tenascin, fibrinogen, and fibrin. The nerve growth inhibitors can include inhibitors of neurotropic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrohin-3 (NT-3), NT4-5, or glial-derived nerve growth factor (GDNF). The nerve growth inhibitors can include inhibitors of neuropoetins such as leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF), oncostatin M (OSM), and interleukin 6 (IL-6).
The nerve growth inhibitors can be inhibitors of neurotropic factor receptors, such as tyrosine kinase receptors (TrkA, TrkB and TRk C), common neurotrophic receptor (P75NTR), ErbB receptors, or fibroblast growth factor receptors. The nerve growth inhibitors can be inhibitors of cell adhesion molecules (CAM), such as N-CAM, Ng-CAM/L1, N-cadherin and L2-HWk-1. The nerve growth inhibitors can be inhibitors of cell signaling molecules such as Ras, Phosphotidyl Inositol 3-kinase, Phospholipase c-gamma 1, Mitogen Activated Phospho kinase, Protein Kinase A, Janus kinases (JAKs), Signal Transducer and Activator of Transcription proteins (Jaks/STATs signaling molecules). Kinase inhibitors include staurosporine, H 89, dihydrochloride, Cyclic Adenosine Monophophate-Rp (cAMPS-Rp), triethylammonium salt, KT 5720, wortmannin, LY294002, 1C486068, 187114, GDC-0941, Gefitinib, Erlotinib, Lapatinib, AZ623, K252a, KT-5555, Cyclotraxin-B, Lestaurtinib, Tofacitinib, Ruxolitinib, SB1518, CYT387, LY3009104, TG101348, WP-1034, PD173074, and Sprouty RTK Signaling Antagonist 4) (SPRY4). The nerve growth inhibitors can be inhibitors of cytokines and chemokines, which include interleukin-6, leukemia inhibitor factor, transforming growth factor 131, and monocyte-chemotactic protein 1.
The nerve growth inhibitors can be inhibitors of sulfate proteoglycans, such as keratin sulfate proteoglycans. The nerve growth inhibitors can be inhibitors of chondroitin sulfate proteoglycans, such as neurocan, brevican, versican, phosphacan, aggrecan, and NG2. The nerve growth inhibitors can be inhibitors of enzymes, including the enzymes Arginase I, Chondroitinase ABC, 13-secretase BACE1, urokinase-type plasminogen activator, and tissue-type plasminogen activator. The nerve growth inhibitors can be inhibitors of arginase, including N-hydroxy-L-arginine and 2(S)-amino-6-boronohexonic acid. The nerve growth inhibitors can be inhibitors of 13-secretase, such as N-Benzyloxycarbonyl-Val-Leu-leucinal, H-Glu-Val-Asn-Statine-Val-Ala-Glu-Phe-NH2, and H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-Stat-Val-Ala-Glu-Phe-OH. The nerve growth inhibitors can be inhibitors of urokinase-type and tissue-type plasminogen activators, including serpin E1, Tiplaxtinin, and plasminogen activator inhibitor-2.
The nerve growth inhibitors can be inhibitors of myelin-derived molecules, such as myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A/B/C, Semaphorin 4D, Semaphorin 3A, and ephrin-B3.
Specific Examples of Nerve Growth Inhibitors
The nerve growth inhibitor used in conjunction with the first medical treatment can include Paclitaxel, Semaphorin-3A, Fibrin, Brain-derived neurotrophic factor (BDNF), Myelin-derived factors including NogoR and PirB, PTEN (dual phosphate and tensin homolog), SOCS3, Notch signaling (Notch/lin12), and ZnEgr.
Carriers and Excipients Combined with Nerve Growth Inhibitors
Carriers, excipients, or both can be combined with nerve growth inhibitors used with the systems describe herein. Carriers could produce a delayed release, for example such that the nerve growth inhibitor is released over a time course such as days, weeks, or months. In various examples, a modulated release of a nerve growth inhibitor occurs over about one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, or six months.
In various examples, a nerve growth inhibitor is encapsulated in microparticles, such as microspheres or nanoparticles, within a biodegradable shell or matrix allowing a modulated release of the nerve growth inhibitor. In various examples, microparticles can be solid with the drug intermixed with the microparticle material. Biostable or biodegradable polymer are examples of a microparticle material. The microparticles can be injected into a vessel wall or target tissue. Microparticle material can be a biodegradable matrix material such as poly-lactic-co-glycolic acid (PLGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), or other biostable or biodegradable polymers.
Some excipients could help in transporting a nerve growth inhibitor deeper into a vessel wall, such as a hepatic vessel wall. The advantage obtained is similar that achieved with electroporation. In various examples, the nerve growth inhibitor is combined with an excipient that facilitates transfer across the luminal surface of the hepatic artery or another vessel and to the target nerve location. Exemplary excipients include polysorbate, sorbitol, urea, iopromide, citrate ester excipient, as used for example in TransPax™ coating available from Boston Scientific Corporation Inc., headquartered in Marlborough, Mass., USA, butyryl-tri-hexyl citrate (BTHC), shellac, or keratose hydrogel.
The first treatment can include hepatic denervation of nerve tissue using electrical energy, radiofrequency energy, irreversible electroporation, microwave energy, ultrasound energy, focused ultrasound (e.g. high-intensity focused ultrasound (HIFU), low-intensity focused ultrasound (LIFU)), laser energy, infrared energy, light energy, thermal energy, steam or heated water, magnetic fields, reversible electroporation, cryogenic therapy, brachytherapy, ionizing therapy, drug delivery, biologic delivery, chemical ablation (e.g. ethanol), mechanical disruption, any other therapy modality to cause disruption or modulation of the target tissue, or any combination thereof.
During delivery of denervation therapy, such as radiofrequency ablation, saline or another fluid can be delivered to cool the inner surface of the lumen. Such cooling fluid can be provided to the inner lumen surface simultaneously with delivering nerve growth inhibitor.
In various examples, such as using the radially expandable member of
The energy can be applied (1) simultaneously, (2) sequentially or (3) in a time switching manner. A time switching manner means the energy is applied to one or more selected electrodes for a short period, such as 20 milliseconds, and then energy is applied to one or more other selected electrodes for another short period. The energy application switches quickly among electrodes.
For irreversible electroporation, the pulse width ranges from 10 nanoseconds to 1 millisecond, or 1 microsecond to 75 microseconds. The pulse can be either biphasic, having both positive and negative phases, or monophasic. The voltage ranges from 200 V to 5000 V, or 1000 V to 3000 V, to have the electrical field strength in tissue from 500 V/cm to 2000 V/cm, such as 1000 V/cm to 1500 V/cm to cause cell damage.
For reversible electroporation, the pulse width ranges from 10 nanoseconds to 1 milliseconds, preferably 1 microsecond to 75 microsecond. The pulse can be either biphasic, having both positive and negative phases, or monophasic. The voltage ranges from 50 V to 5000 V, such as 100 V to 3000 V, to have the electrical field strength in tissue from 50 V/cm to 800 V/cm, such as 100 V/cm to 400 V/cm, to cause reversible cell damage to allow drug to penetrate the membrane.
It should be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
It should also be noted that, as used in this specification and the appended claims, the phrase “configured” describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a particular configuration. The phrase “configured” can be used interchangeably with other similar phrases such as arranged and configured, constructed and arranged, constructed, manufactured and arranged, and the like.
All publications and patent applications in this specification are indicative of the level of ordinary skill in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated by reference.
The embodiments described herein are not intended to be exhaustive or to limit the invention to the precise forms disclosed in the following detailed description. Rather, the embodiments are chosen and described so that others skilled in the art can appreciate and understand the principles and practices. As such, aspects have been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope herein.
This application claims the benefit of U.S. Provisional Application No. 62/724,233, filed Aug. 29, 2018, the content of which is herein incorporated by reference in its entirety
| Number | Date | Country | |
|---|---|---|---|
| 62724233 | Aug 2018 | US |
